lansoprazole has been researched along with Adverse Drug Event in 9 studies
Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the efficacy and safety of lansoprazole in treating infants with symptoms attributed to gastroesophageal reflux disease (GERD) that have persisted despite a >or= 1-week course of nonpharmacologic management." | 9.14 | Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. ( Atkinson, S; Furmaga-Jablonska, W; Hassall, E; Orenstein, SR; Raanan, M, 2009) |
| "To assess the efficacy and safety of lansoprazole in treating infants with symptoms attributed to gastroesophageal reflux disease (GERD) that have persisted despite a >or= 1-week course of nonpharmacologic management." | 5.14 | Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. ( Atkinson, S; Furmaga-Jablonska, W; Hassall, E; Orenstein, SR; Raanan, M, 2009) |
| " Combination therapy of ceftriaxone and lansoprazole is associated with increased risk of acquired long QT syndrome." | 3.83 | Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation. ( Chang, JB; Iyer, V; Kass, RS; Lorberbaum, T; Sampson, KJ; Tatonetti, NP; Woosley, RL, 2016) |
| "Lansoprazole was the drug with the highest number of associated reports (30." | 1.91 | Spontaneous reporting of adverse reactions related to proton pump inhibitors. ( Cicala, G; Cutroneo, P; Dipasquale, V; Laganà, F; Romano, C; Spina, E; Trimarchi, G, 2023) |
| "5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects." | 1.32 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. ( Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Matthews, EJ | 1 |
| Kruhlak, NL | 1 |
| Weaver, JL | 1 |
| Benz, RD | 1 |
| Contrera, JF | 1 |
| Pedersen, JM | 1 |
| Matsson, P | 1 |
| Bergström, CA | 1 |
| Norinder, U | 1 |
| Hoogstraate, J | 1 |
| Artursson, P | 1 |
| Liu, Z | 1 |
| Shi, Q | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Fang, H | 1 |
| Tong, W | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Yamashiro, K | 1 |
| Jouta, M | 1 |
| Hosomi, K | 1 |
| Yokoyama, S | 1 |
| Ozaki, Y | 1 |
| Hirata, A | 1 |
| Ogata, F | 1 |
| Nakamura, T | 1 |
| Tanei, S | 1 |
| Kawasaki, N | 1 |
| Dipasquale, V | 3 |
| Cicala, G | 3 |
| Laganà, F | 3 |
| Cutroneo, P | 3 |
| Trimarchi, G | 3 |
| Spina, E | 3 |
| Romano, C | 3 |
| Gallelli, L | 1 |
| Gallelli, G | 1 |
| Codamo, G | 1 |
| Argentieri, A | 1 |
| Michniewicz, A | 1 |
| Siniscalchi, A | 1 |
| Stefanelli, R | 1 |
| Cione, E | 1 |
| Caroleo, MC | 1 |
| Longo, P | 1 |
| De Sarro, G | 1 |
| Lorberbaum, T | 1 |
| Sampson, KJ | 1 |
| Chang, JB | 1 |
| Iyer, V | 1 |
| Woosley, RL | 1 |
| Kass, RS | 1 |
| Tatonetti, NP | 1 |
| Orenstein, SR | 1 |
| Hassall, E | 1 |
| Furmaga-Jablonska, W | 1 |
| Atkinson, S | 1 |
| Raanan, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Study Assessing the Safety and Efficacy of Lansoprazole Microgranules Oral Suspension in Infants With Symptomatic Gastroesophageal Reflux[NCT00324974] | Phase 3 | 162 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for lansoprazole and Adverse Drug Event
| Article | Year |
|---|---|
Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Double-Blind Method; Drug-Related Side Effects and Adverse | 2009 |
8 other studies available for lansoprazole and Adverse Drug Event
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Dru | 2004 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Bi | 2008 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Adverse event profiles of microscopic colitis in the Japanese Adverse Drug Event Report (JADER) database.
Topics: Adverse Drug Reaction Reporting Systems; Aspirin; Colitis, Microscopic; Drug-Related Side Effects an | 2022 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Spontaneous reporting of adverse reactions related to proton pump inhibitors.
Topics: Adverse Drug Reaction Reporting Systems; Drug-Related Side Effects and Adverse Reactions; Humans; La | 2023 |
Recognizing Severe Adverse Drug Reactions: Two Case Reports After Switching Therapies to the Same Generic Company.
Topics: Adult; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Drugs, Generic; Female; H | 2016 |
Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation.
Topics: Aged; Ceftriaxone; Cefuroxime; Data Mining; Drug Interactions; Drug-Related Side Effects and Adverse | 2016 |